TGF-β and SMAD2/3 show oncogenic activities, such as promoting glioma cell proliferation, by affecting the methylation status of the platelet-derived growth factor-β (PDGF-B) gene and autocrine PDGF-B signaling within tumor microenvironments [55]. The gene discussed is TGFB1; the disease is neoplasm.